Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
$200.00
Several drugs recently lost their Breakthrough Therapy Designations (BTDs), and Pink Sheet has identified others in the pipeline that might suffer the same fate soon. Take a look at the therapies possibly on the chopping block and the reasons behind it in this informative article.
Author: Bridget Silverman
Publisher: Pinksheet
- Description
Explore what happens when a drug loses its Breakthrough Therapy Designation (BTD) from the FDA. Pink Sheet examines some recent rejects from the BTD list and follows their trajectories after the loss of the label – does it mean the end of the line, or just a new path for the drugs? Pink Sheet’s experts also take a look at other therapies that may soon be due to lose their BTD status, and probes the reasons driving these possible upcoming withdrawals and rescissions.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
The Knowledge Within: An Interview With Merck KGaA’s R&D Chief 
Sign up to the